Patents by Inventor Rubina G. Parmar
Rubina G. Parmar has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240009225Abstract: One aspect of the present invention relates to a double stranded iRNA agent comprising an antisense strand which is complementary to a target gene; a sense strand which is complementary to said antisense strand; and one or more lipophilic moieties conjugated to one or more internal positions on at least one strand, optionally via a linker or carrier. Another aspect of the invention relates to a method of gene silencing, comprising administering to a cell or a subject in need thereof a therapeutically effective amount of the lipophilic moieties-conjugated double-stranded iRNAs.Type: ApplicationFiled: May 3, 2023Publication date: January 11, 2024Inventors: Jayaprakash K. NAIR, Martin MAIER, Vasant JADHAV, Stuart MILSTEIN, Kirk BROWN, Rubina G. PARMAR, Kallanthottathil G. RAJEEV, Muthiah MANOHARAN, Alexander V. KEL'IN, Muthusamy JAYARAMAN, Klaus CHARISSE, Adam CASTORENO, Christopher THEILE, Kevin FITZGERALD
-
Publication number: 20220307024Abstract: One aspect of the present invention relates to a double stranded iRNA agent comprising an antisense strand which is complementary to a target gene; a sense strand which is complementary to said antisense strand; and one or more lipophilic moieties conjugated to one or more internal positions on at least one strand, optionally via a linker or carrier, which provides for targeting to, and uptake by, tissues and cells of the CNS, and in particular the striatum. Another aspect of the invention relates to a method of gene silencing in tissues and cells of the CNS, and in particular the striatum, that includes administering to a tissue/cell or a subject in need thereof a therapeutically effective amount of the lipophilic moieties-conjugated double-stranded iRNAs.Type: ApplicationFiled: June 16, 2020Publication date: September 29, 2022Applicant: ALNYLAM PHARMACEUTICALS, INC.Inventors: Jayaprakash K. Nair, Martin Maier, Vasant Jadhav, Stuart Milstein, Kirk Brown, Rubina G. Parmar, Kallanthottathil G. Rajeev, Muthiah Manoharan, Alexander V. Kel'in, Muthusamy Jayaraman, Klaus Charisse, Adam Castoreno, Christopher S. Theile, Kevin Fitzgerald
-
Publication number: 20220289785Abstract: Disclosed herein is a modular composition comprising 1) an oligonucleotide; 2) one or more tetraGalNAc ligands of Formula (I), which may be the same or different; optionally, 3) one or more linkers, which may be the same or different; 4) one or more peptides independently selected from Table 3, which may be the same or different; and optionally, 5) one or more targeting ligands, solubilizing agents, pharmacokinetics enhancing agents, lipids, and/or masking agents.Type: ApplicationFiled: July 28, 2021Publication date: September 15, 2022Inventors: David TELLERS, Steven L. COLLETTI, Vadim DUDKIN, Jeffrey AARONSON, Aaron MOMOSE, Thomas Joseph TUCKER, Yu YUAN, Kathleen B. CALATI, Lu TIAN, Rubina G. PARMAR, Anthony W. SHAW, Weimin WANG, Rachel Anne STORR, Marina BUSUEK, Robert A. KOWTONIUK
-
Publication number: 20220125823Abstract: The invention relates to a method of gene silencing, comprising administering to a cell or a subject in need thereof a therapeutically effective amount of the lipophilic moieties-conjugated double-stranded iRNAs at one or more internal positions on at least one strand, optionally via a linker or carrier.Type: ApplicationFiled: May 7, 2019Publication date: April 28, 2022Inventors: Jayaprakash K. NAIR, Martin MAIER, Vasant JADHAV, Stuart MILSTEIN, Kirk BROWN, Rubina G. PARMAR, Kallanthottathil G. RAJEEV, Muthiah MANOHARAN, Alexander V. KEL'IN, Muthusamy JAYARAMAN, Klaus CHARISSE, Adam CASTORENO, Christopher S. THEILE, Kevin FITZGERALD
-
Patent number: 11117917Abstract: Disclosed herein is a modular composition comprising 1) an oligonucleotide; 2) one or more tetraGalNAc ligands of Formula (I), which may be the same or different; optionally, 3) one or more linkers, which may be the same or different; 4) one or more peptides independently selected from Table 3, which may be the same or different; and optionally, 5) one or more targeting ligands, solubilizing agents, pharmacokinetics enhancing agents, lipids, and/or masking agents.Type: GrantFiled: February 5, 2019Date of Patent: September 14, 2021Assignee: Sirna Therapeutics, Inc.Inventors: David Tellers, Steven L. Colletti, Vadim Dudkin, Jeffrey Aaronson, Aaron Momose, Thomas Joseph Tucker, Yu Yuan, Kathleen B. Calati, Lu Tian, Rubina G. Parmar, Anthony W. Shaw, Weimin Wang, Rachel Anne Storr, Marina Busuek, Robert A. Kowtoniuk
-
Publication number: 20210238594Abstract: One aspect of the present invention relates to double-stranded RNA (dsRNA) agent capable of inhibiting the expression of a target gene. Other aspects of the invention relate to pharmaceutical compositions comprising these dsRNA molecules suitable for therapeutic use, and methods of inhibiting the expression of a target gene by administering these dsRNA molecules, e.g., for the treatment of various disease conditions.Type: ApplicationFiled: May 7, 2019Publication date: August 5, 2021Applicant: Alnylam Pharmaceuticals, Inc.Inventors: Rubina G. PARMAR, Pawan KUMAR, Masaaki AKABANE-NAKATA, Shigeo MATSUDA, Muthiah MANOHARAN
-
Patent number: 10532068Abstract: Disclosed herein is a method for inhibiting expression of a gene of a subject comprising administering (1) a composition comprising R-(L)a-(G)b; wherein R is an oligonucleotide selected from the group consisting of DNA, RNA, siRNA, and microRNA; L is a linker and each occurrence of L is independently selected from Table 3; G is a targeting ligand and each occurrence of G is independently selected from Table 4; each of a and b is independently 0, 1, 2, 3 or 4; and (2) a composition comprising (P)c-(L)d-(G)e; wherein P is a peptide and each occurrence of P is independently selected from Table 2; L is a linker and each occurrence of L is independently selected from Table 3; G is a targeting ligand and each occurrence of G is independently selected from Table 4; d is 0, 1, 2, 3, 4, 5 or 6; and each of c and e is independently 1, 2, 3, 4, 5 or 6. Compositions in (1) and (2) can be co-administered or sequentially administered.Type: GrantFiled: May 8, 2018Date of Patent: January 14, 2020Assignee: Merck Sharp & Dohme Corp.Inventors: Steven L. Colletti, Thomas J. Tucker, David M. Tellers, Boyoung Kim, Rob Burke, Kathleen B. Calati, Matthew G. Stanton, Rubina G. Parmar, Jeffrey G. Aaronson, Weimin Wang
-
Publication number: 20190153016Abstract: Disclosed herein is a modular composition comprising 1) an oligonucleotide; 2) one or more tetraGalNAc ligands of Formula (I), which may be the same or different; optionally, 3) one or more linkers, which may be the same or different; 4) one or more peptides independently selected from Table 3, which may be the same or different; and optionally, 5) one or more targeting ligands, solubilizing agents, pharmacokinetics enhancing agents, lipids, and/or masking agents.Type: ApplicationFiled: February 5, 2019Publication date: May 23, 2019Inventors: David TELLERS, Steven L. COLLETTI, Vadim DUDKIN, Jeffrey AARONSON, Aaron MOMOSE, Thomas Joseph TUCKER, Yu YUAN, Kathleen B. CALATI, Lu TIAN, Rubina G. PARMAR, Anthony W. SHAW, Weimin WANG, Rachel Anne STORR, Marina BUSUEK, Robert A. KOWTONIUK
-
Patent number: 10239957Abstract: Disclosed herein is a peptide containing conjugate comprising (P)c-(L)d-(G)e, wherein P is a peptide and each occurance of P is independently selected from Table 2; L is an optional linker and each occurance of L, if present, is independently selected from Table 3; G is a targeting ligand and each occurance of G is independently selected from Table 4; d is 0, 1, 2, 3, 4, 5 or 6; and each of c and e is independently 1, 2, 3, 4, 5 or 6. The conjugate can be administered to a subject either alone or in combination with a composition comprising R-(L)a-(G)b, wherein R is an oligonucleotide as defined herein, to inhibit expression of a gene of the subject.Type: GrantFiled: November 3, 2014Date of Patent: March 26, 2019Assignee: Merck Sharp & Dohme Corp.Inventors: Steven L. Colletti, Thomas J. Tucker, David M. Tellers, Boyoung Kim, Rob Burke, Kathleen B. Calati, Matthew G. Stanton, Rubina G. Parmar, Jeffery G. Aaronson, Weimin Wang
-
Patent number: 10221205Abstract: Disclosed herein is a modular composition comprising 1) an oligonucleotide; 2) one or more tetraGalNAc ligands of Formula (I), which may be the same or different; optionally, 3) one or more linkers, which may be the same or different; 4) one or more peptides independently selected from Table 3, which may be the same or different; and optionally, 5) one or more targeting ligands, solubilizing agents, pharmacokinetics enhancing agents, lipids, and/or masking agents.Type: GrantFiled: November 8, 2017Date of Patent: March 5, 2019Assignee: Sirna Therapeutics, Inc.Inventors: David Tellers, Steven L. Colletti, Vadim Dudkin, Jeffrey Aaronson, Aaron Momose, Thomas Joseph Tucker, Yu Yuan, Kathleen B. Calati, Lu Tian, Rubina G. Parmar, Anthony W. Shaw, Weimin Wang, Rachel Anne Storr, Marina Busuek, Robert A. Kowtoniuk
-
Publication number: 20190015442Abstract: Disclosed herein is a method for inhibiting expression of a gene of a subject comprising administering (1) a composition comprising R-(L)a-(G)b; wherein R is an oligonucleotide selected from the group consisting of DNA, RNA, siRNA, and microRNA; L is a linker and each occurance of L is independently selected from Table 3; G is a targeting ligand and each occurance of G is independently selected from Table 4; each of a and b is independently 0, 1, 2, 3 or 4; and (2) a composition comprising (P)c-(L)d-(G)e; wherein P is a peptide and each occurance of P is independently selected from Table 2; L is a linker and each occurance of L is independently selected from Table 3; G is a targeting ligand and each occurance of G is independently selected from Table 4; d is 0, 1, 2, 3, 4, 5 or 6; and each of c and e is independently 1, 2, 3, 4, 5 or 6. Compositions in (1) and (2) can be co-administered or sequentially administered.Type: ApplicationFiled: May 8, 2018Publication date: January 17, 2019Applicant: Merck Sharp & Dohme Corp.Inventors: Steven L. Colletti, Thomas J. Tucker, David M. Tellers, Boyoung Kim, Rob Burke, Kathleen B. Calati, Matthew G. Stanton, Rubina G. Parmar, Jeffrey G. Aaronson, Weimin Wang
-
Patent number: 10010562Abstract: Disclosed herein is a method for inhibiting expression of a gene of a subject comprising administering (1) a composition comprising R-(L)a-(G)b; wherein R is an oligonucleotide selected from the group consisting of DNA, RNA, siRNA, and microRNA; L is a linker and each occurrence of L is independently selected from Table 3; G is a targeting ligand and each occurrence of G is independently selected from Table 4; each of a and b is independently 0, 1, 2, 3 or 4; and (2) a composition comprising (P)c-(L)d-(G)e; wherein P is a peptide and each occurrence of P is independently selected from Table 2; L is a linker and each occurrence of L is independently selected from Table 3; G is a targeting ligand and each occurrence of G is independently selected from Table 4; d is 0, 1, 2, 3, 4, 5 or 6; and each of c and e is independently 1, 2, 3, 4, 5 or 6. Compositions in (1) and (2) can be co-administered or sequentially administered.Type: GrantFiled: November 3, 2014Date of Patent: July 3, 2018Assignee: Merck Sharp & Dohme Corp.Inventors: Steven L. Colletti, Thomas J. Tucker, David M. Tellers, Boyoung Kim, Rob Burke, Kathleen B. Calati, Matthew G. Stanton, Rubina G. Parmar, Jeffrey G. Aaronson, Weimin Wang
-
Publication number: 20180079769Abstract: Disclosed herein is a modular composition comprising 1) an oligonucleotide; 2) one or more tetraGalNAc ligands of Formula (I), which may be the same or different; optionally, 3) one or more linkers, which may be the same or different; 4) one or more peptides independently selected from Table 3, which may be the same or different; and optionally, 5) one or more targeting ligands, solubilizing agents, pharmacokinetics enhancing agents, lipids, and/or masking agents.Type: ApplicationFiled: November 8, 2017Publication date: March 22, 2018Inventors: David TELLERS, Steven L. COLLETTI, Vadim DUDKIN, Jeffrey AARONSON, Aaron MOMOSE, Thomas Joseph TUCKER, Yu YUAN, Kathleen B. CALATI, Lu TIAN, Rubina G. PARMAR, Anthony W. SHAW, Weimin WANG, Rachel Anne STORR, Marina BUSUEK, Robert A. KOWTONIUK
-
Patent number: 9840531Abstract: Disclosed herein is a modular composition comprising 1) an oligonucleotide; 2) one or more tetraGalNAc ligands of Formula (I), which may be the same or different; optionally, 3) one or more linkers, which may be the same or different; 4) one or more peptides independently selected from Table 3, which may be the same or different; and optionally, 5) one or more targeting ligands, solubilizing agents, pharmacokinetics enhancing agents, lipids, and/or masking agents.Type: GrantFiled: April 7, 2017Date of Patent: December 12, 2017Assignee: Sirna Therapeutics, Inc.Inventors: David Tellers, Steven L. Colletti, Vadim Dudkin, Jeffrey Aaronson, Aaron Momose, Thomas Joseph Tucker, Yu Yuan, Kathleen B. Calati, Lu Tian, Rubina G. Parmar, Anthony W. Shaw, Weimin Wang, Rachel Anne Storr, Marina Busuek, Robert A. Kowtoniuk
-
Publication number: 20170306324Abstract: Disclosed herein is a modular composition comprising 1) an oligonucleotide; 2) one or more tetraGalNAc ligands of Formula (I), which may be the same or different; optionally, 3) one or more linkers, which may be the same or different; 4) one or more peptides independently selected from Table 3, which may be the same or different; and optionally, 5) one or more targeting ligands, solubilizing agents, pharmacokinetics enhancing agents, lipids, and/or masking agents.Type: ApplicationFiled: April 7, 2017Publication date: October 26, 2017Inventors: David TELLERS, Steven L. COLLETTI, Vadim DUDKIN, Jeffrey AARONSON, Aaron MOMOSE, Thomas Joseph TUCKER, Yu YUAN, Kathleen B. CALATI, Lu TIAN, Rubina G. PARMAR, Anthony W. SHAW, Weimin WANG, Rachel Anne STORR, Marina BUSUEK, Robert A. KOWTONIUK
-
Publication number: 20170189441Abstract: Disclosed herein is a method for inhibiting expression of a gene of a subject comprising administering (1) a composition comprising R-(L)a-(G)b; wherein R is an oligonucleotide selected from the group consisting of DNA, RNA, siRNA, and microRNA; L is a linker and each occurrence of L is independently selected from Table 3; G is a targeting ligand and each occurrence of G is independently selected from Table 4; each of a and b is independently 0, 1, 2, 3 or 4; and (2) a composition comprising (P)c-(L)d-(G)e; wherein P is a peptide and each occurrence of P is independently selected from Table 2; L is a linker and each occurrence of L is independently selected from Table 3; G is a targeting ligand and each occurrence of G is independently selected from Table 4; d is 0, 1, 2, 3, 4, 5 or 6; and each of c and e is independently 1, 2, 3, 4, 5 or 6. Compositions in (1) and (2) can be co-administered or sequentially administered.Type: ApplicationFiled: November 3, 2014Publication date: July 6, 2017Applicant: Merck Sharp & Dohme Corp.Inventors: Steven L. Colletti, Thomas J. Tucker, David M. Tellers, Boyoung Kim, Rob Burke, Kathleen B. Calati, Matthew G. Stanton, Rubina G. Parmar, Jeffery G. Aaronson, Weimin Wang
-
Patent number: 9655976Abstract: Disclosed herein is a modular composition comprising 1) an oligonucleotide; 2) one or more tetraGalNAc ligands of Formula (I), which may be the same or different; optionally, 3) one or more linkers, which may be the same or different; 4) one or more peptides independently selected from Table 3, which may be the same or different; and optionally, 5) one or more targeting ligands, solubilizing agents, pharmacokinetics enhancing agents, lipids, and/or masking agents.Type: GrantFiled: May 1, 2013Date of Patent: May 23, 2017Assignee: Sirna Therapeutics, Inc.Inventors: David Tellers, Steven L. Colletti, Vadim Dudkin, Jeffrey Aaronson, Aaron Momose, Thomas Joseph Tucker, Yu Yuan, Kathleen B. Calati, Lu Tian, Rubina G. Parmar, Anthony W. Shaw, Weimin Wang, Rachel Anne Storr, Marina Busuek, Robert A. Kowtoniuk
-
Publication number: 20170081425Abstract: Disclosed herein is a peptide containing conjugate comprising (P)c-(L)d-(G)e, wherein P is a peptide and each occurance of P is independently selected from Table 2; L is an optional linker and each occurance of L, if present, is independently selected from Table 3; G is a targeting ligand and each occurance of G is independently selected from Table 4; d is 0, 1, 2, 3, 4, 5 or 6; and each of c and e is independently 1, 2, 3, 4, 5 or 6. The conjugate can be administered to a subject either alone or in combination with a composition comprising R-(L)a-(G)b, wherein R is an oligonucleotide as defined herein, to inhibit expression of a gene of the subject.Type: ApplicationFiled: November 3, 2014Publication date: March 23, 2017Applicant: Merck Sharp & Dohme Corp.Inventors: Steven L. Colletti, Thomas J. Tucker, David M. Tellers, Boyoung Kim, Rob Burke, Kathleen B. Calati, Matthew G. Stanton, Rubina G. Parmar, Jeffery G. Aaronson, Weimin Wang
-
Patent number: 9402914Abstract: The present invention provides membrane lytic poly(amido amine) polymers, polyconjugates, compositions and methods for the delivery of oligonucleotides for therapeutic purposes.Type: GrantFiled: October 3, 2014Date of Patent: August 2, 2016Assignee: SIRNA THERAPEUTICS, INC.Inventors: Marina Busuek, Rubina G. Parmar, Michael Steven Poslusney, Weimin Wang, J. Michael Williams
-
Publication number: 20150246133Abstract: Disclosed herein is a modular composition comprising 1) an oligonucleotide; 2) one or more tetraGalNAc ligands of Formula (I), which may be the same or different; optionally, 3) one or more linkers, which may be the same or different; 4) one or more peptides independently selected from Table 3, which may be the same or different; and optionally, 5) one or more targeting ligands, solubilizing agents, pharmacokinetics enhancing agents, lipids, and/or masking agents.Type: ApplicationFiled: May 1, 2013Publication date: September 3, 2015Inventors: David Tellers, Steven L. Colletti, Vadim Dudkin, Jeffrey Aaronson, Aaron Momose, Thomas Joseph Tucker, Yu Yuan, Kathleen B. Calati, Lu Tian, Rubina G. Parmar, Anthony W. Shaw, Weimin Wang, Rachel Anne Storr, Marina Busuek, Robert A. Kowtoniuk